Centessa Pharmaceuticals plc Share Price
Equities
CNTA
US1523091007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.27 USD | +2.52% |
|
+13.83% | +1.04% |
| 01-13 | Nxera Pharma to Receive $3.6 Million Milestone Payment From Centessa | MT |
| 01-11 | Certain Options of Centessa Pharmaceuticals plc are subject to a Lock-Up Agreement Ending on 11-JAN-2026. | CI |
| Capitalization | 3.69B 3.14B 2.91B 2.72B 5.07B 339B 5.37B 33.26B 13.2B 160B 13.84B 13.56B 582B | P/E ratio 2025 * |
-18.3x | P/E ratio 2026 * | -15.8x |
|---|---|---|---|---|---|
| Enterprise value | 3.43B 2.92B 2.71B 2.53B 4.71B 315B 5B 30.92B 12.28B 149B 12.87B 12.61B 542B | EV / Sales 2025 * |
218x | EV / Sales 2026 * | 1,771x |
| Free-Float |
86.58% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
More news
| 1 day | +2.52% | ||
| 1 week | +13.83% | ||
| Current month | +1.04% | ||
| 1 month | +0.04% | ||
| 3 months | +4.68% | ||
| 6 months | +62.30% | ||
| Current year | +1.04% |
| 1 week | 21.5 |  | 26 |
| 1 month | 21.5 | | 26 |
| Current year | 21.5 | | 26 |
| 1 year | 9.6 | | 30.58 |
| 3 years | 3 | | 30.58 |
| 5 years | 2.88 | | 30.58 |
| 10 years | 2.88 | | 30.58 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 40 | 31/12/2025 | |
John Crowley
DFI | Director of Finance/CFO | 53 | 09/06/2024 |
Steve Kanes
CTO | Chief Tech/Sci/R&D Officer | 61 | 07/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 56 | 31/10/2020 | |
Arjun Goyal
BRD | Director/Board Member | - | 31/12/2020 |
Brett Zbar
BRD | Director/Board Member | 53 | 31/12/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.52% | +13.83% | +55.22% | +552.97% | 3.69B | |
| +0.04% | -0.68% | -4.77% | +12.20% | 49.48B | |
| -1.56% | -1.00% | +14.23% | +2.87% | 40.07B | |
| +0.15% | +0.33% | +52.68% | +26.14% | 37.55B | |
| +1.92% | +1.44% | +23.10% | +42.46% | 31.67B | |
| -0.99% | -2.20% | +185.93% | +328.06% | 22.74B | |
| -3.01% | -3.74% | +69.03% | +145.51% | 16.56B | |
| Average | -0.13% | +1.59% | +56.49% | +158.60% | 28.82B | |
| Weighted average by Cap. | -0.28% | -0.02% | +42.72% | +74.13% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 15.71M 13.36M 12.38M 11.57M 21.57M 1.44B 22.86M 142M 56.18M 681M 58.9M 57.69M 2.48B | 1.9M 1.62M 1.5M 1.4M 2.61M 175M 2.77M 17.12M 6.8M 82.42M 7.12M 6.98M 300M |
| Net income | -182M -155M -144M -134M -251M -16.77B -266M -1.64B -653M -7.92B -684M -670M -28.79B | -231M -197M -182M -170M -317M -21.24B -336M -2.08B -827M -10.03B -867M -849M -36.48B |
| Net Debt | -259M -221M -204M -191M -356M -23.83B -378M -2.34B -928M -11.25B -973M -953M -40.93B | -327M -278M -258M -241M -449M -30.01B -476M -2.94B -1.17B -14.17B -1.22B -1.2B -51.55B |
More financial data
* Estimated data
Employees
114
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 25.27 $ | +2.52% | 1,887,863 |
| 22/01/26 | 24.65 $ | +6.11% | 2,037,770 |
| 21/01/26 | 23.23 $ | +1.35% | 6,463,853 |
| 20/01/26 | 22.92 $ | +3.24% | 638,908 |
| 16/01/26 | 22.20 $ | -0.89% | 1,681,099 |
Delayed Quote Nasdaq, January 23, 2026 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
25.27USD
Average target price
39.23USD
Spread / Average Target
+55.25%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CNTA Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition